Lantern Pharma Inc. (NASDAQ: LTRN) has launched an innovative artificial intelligence module designed to predict the efficacy of cancer treatment combinations, specifically those involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis). This module, part of the company's RADR(R) platform, utilizes genomic, transcriptomic, and clinical data to forecast treatment synergy and patient response, offering a groundbreaking approach to oncology drug development.
The development of this AI tool was informed by a comprehensive review of 221 clinical trials, highlighting the potential of non-PARP DDRi combinations with DNA-damaging agents in treating specific cancer subtypes. Notably, this technology has already played a pivotal role in designing Lantern’s FDA-cleared Phase 1B/2 trial for triple-negative breast cancer, showcasing its immediate applicability and potential to revolutionize cancer treatment strategies.
With the global market for combination cancer therapies expected to exceed $50 billion by 2030, Lantern Pharma's AI module arrives at a critical juncture. The company is currently exploring licensing opportunities to make this technology available for broader use in oncology, promising to enhance the precision and effectiveness of cancer treatments worldwide.
For more information on Lantern Pharma's advancements and updates, visit their newsroom at https://ibn.fm/LTRN.
